Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

Clinical trial NCT03610971 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03610971
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Phase Chronic Myeloid Leukemia Chronic Myeloid Leukemia, Chronic Phase

Start date: 2019-11-19
Primary completion: 2025-09-25
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.